AI
NMRA icon

Auour Investments’s Neumora Therapeutics NMRA Stock Holding History

Auour Investments’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-250,000
Closed -$2.93M – 86
2024
Q3 		$2.93M Buy
+250,000
New +$2.92M 1.05% 27
2024
Q2 		– Sell
-105,087
Closed -$1.44M – 80
2024
Q1 		$1.44M Buy
+105,087
New +$1.7M 0.53% 38

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Auour Investments's NMRA Position: Q4 2024 in Review

Auour Investments sold out of Neumora Therapeutics (NMRA) in Q4 2024, closing a stake of 250,000 shares — an estimated $2.93M sold.

Auour Investments first reported a position in NMRA in Q1 2024 and held it in 2 quarters. The position peaked at $2.93M in Q3 2024. 134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

  • Auour Investments reported no remaining Neumora Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Auour Investments sold 250,000 Neumora Therapeutics shares in Q4 2024, an estimated $2.93M.
  • Auour Investments first reported a position in Neumora Therapeutics in Q1 2024 and held it in 2 quarters.
  • Auour Investments's Neumora Therapeutics position peaked at $2.93M in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Auour Investments's 13F filing for Q4 2024, filed 3 Feb 2025.